Audit: QRS - Hydroxyapatite for Health & Longevity
Audit conducted on 26/09/2026 05:53 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 85 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol, time-to-effect, benefit, risk, gate, and monitoring content all trace to ER sections (Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions & Contraindications, Monitoring). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious qualifiers survive where the QRS format allows them (e.g., “a match still open”, “no study shows fewer fractures”, “in trial protocols”); tiers carry evidence strength. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; e.g., “Toothpaste forms: known allergy to a formulation ingredient” matches ER line 324. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications from ER lines 319-324, interactions from ER lines 306-315; modifying factors are not surfaced as risks or cautions. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs or expert names; only brand “Tums”, which appears in ER line 311 for the same fact. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address found. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Drug classes and technical conditions are glossed (e.g., “Levothyroxine (thyroid hormone)”, “eGFR, a kidney-function measure”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No “pill”, “by mouth”, “shot” or similar lay terms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, tier labels and column headers unchanged (lines 440, 477, 519, 539, 552, 574, 593, 597-599, 712). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template variable spans present; marker_# and qualitative_item_# expanded to 1-9 and 1-5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Head (except title/metadata) and non-variable spans (website=”…”) identical to template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No QRS-mapped ER section is empty; the empty High risk tier is handled by 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Toothpaste regimen”, “Time of day”, “Supplement protocol (OHC)” and interaction labels match ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed; interaction and contraindication items trimmed to key facts. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only quoted value is duration “00:02”, which contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.9.25 matches QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-0926-0528 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/26/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “the natural mineral of teeth and bone, is used in toothpaste to rebuild enamel and as a calcium supplement”. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Supported by ER Motivation (line 39) and Conclusion (lines 431-435). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations (lines 319-324) represented. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds (10.5 mg/dL, eGFR below 30), staging (stage 4-5) and episode count preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated, as the ER names avoid-populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER interactions (lines 306-315) listed; none duplicate contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists and severity classes preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated, as the ER names interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Toothpaste regimen, time of day, and OHC supplement protocol (ER lines 341, 345-346, 348). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three or more actionable aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Sensitivity 2-8 weeks, caries 6-18 months, bone density 12-36 months (ER line 376). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | All three are High-tier benefits, ordered as in ER Expected Benefits. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers have items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER High tier has no items; risks_high span set to display: none (line 576). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers (lines 399-407) listed with matching targets. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers (lines 411-415) listed verbatim. |
Issues 26/09/2026 05:53
Pass rate 100.00%. No issues found.
Issues 26/09/2026 05:50
- 4.3 — Contraindication labels paraphrased: The ER “Populations who should avoid” labels “Supplement forms:”, “Bovine-derived supplement forms” and “Toothpaste forms:” were shortened to “Supplements:”, “Bovine-derived supplements” and “Toothpaste:” in stop_items (QRS lines 542-547).
Fixes 26/09/2026 05:50
- 4.3 — Contraindication labels restored verbatim: Changed the stop_items prefixes “Supplements:”, “Bovine-derived supplements” and “Toothpaste:” back to the ER labels “Supplement forms:”, “Bovine-derived supplement forms” and “Toothpaste forms:”.
Issues 26/09/2026 05:47
- 7.1 — Lede omits intended use: Line 433 opens “is used in toothpaste and calcium supplements”, naming the products but not what hydroxyapatite is used for (rebuilding enamel, per ER Motivation) before giving the evidence verdict.
Fixes 26/09/2026 05:47
- 7.1 — Lede states intended use: Changed the opening from “is used in toothpaste and calcium supplements” to “is used in toothpaste to rebuild enamel and as a calcium supplement”, tightening the rest of the lede to stay within 70 words.
Issues 26/09/2026 05:44
- 2.7 — Unexplained specialist terms: “eGFR” is never expanded (stop_items line 545, marker_6_name line 660), “MCHC” is never expanded (stop_items line 546), and “primary hyperparathyroidism” is left unexplained (line 543), although the ER provides plain-language glosses for each.
Fixes 26/09/2026 05:44
- 2.7 — Unexplained specialist terms: Added ER-based glosses: “primary hyperparathyroidism (overactive parathyroid glands)”, “eGFR, a kidney-function measure” in stop_items, and “eGFR (kidney function)” as marker_6_name. Replaced “MCHC” in stop_items with “microcrystalline hydroxyapatite concentrate”.
Issues 26/09/2026 05:43
- 7.2 — Fluoride-match caveat omitted: The At a Glance (line 433) states flatly that hydroxyapatite toothpaste “protects against new cavities about as well as fluoride” but omits the ER Conclusion’s main caveat that this match with fluoride “remains an open question”.
Fixes 26/09/2026 05:43
- 7.2 — Fluoride-match caveat added: Rewrote the At a Glance to add the ER Conclusion’s caveat that the toothpaste’s match with fluoride “remains open”; the text was tightened so it stays within 70 words.
Issues 26/09/2026 05:37
- 2.7 — Unexplained jargon and acronym: Line 543 uses “granulomatous disease such as sarcoidosis” without the ER’s plain-language gloss, and “OHC” (line 466, Supplement protocol label) is never expanded on the sheet.
- 4.5 — Gate sections not condensed: Key Interactions (lines 555-564) keep long explanatory parentheticals and Contraindications (lines 542-545) repeat “Supplement forms:” four times, pushing the sheet beyond one A4 page.
Fixes 26/09/2026 05:37
- 2.7 — Jargon and acronym explained: Added the ER gloss “(inflammatory nodules activating vitamin D)” to granulomatous disease in Contraindications, and expanded OHC as “Ossein-hydroxyapatite complex” in the Supplement protocol sub-line.
- 4.5 — Gate sections condensed: Shortened the “Supplement forms:”/”Toothpaste forms:” prefixes to “Supplements:”/”Toothpaste:” and trimmed the Thiazide diuretics parenthetical to “(blood-pressure drugs: hydrochlorothiazide, chlorthalidone)”.
Issues 26/09/2026 05:34
- 2.7 / 4.2 / 4.3 — Gate labels lose ER glosses: In the gates, “hypercalcemia” (line 542) drops the ER gloss “high blood calcium”, and the Key Interactions labels “Bisphosphonates (alendronate, risedronate)” and “Thiazide diuretics (hydrochlorothiazide, chlorthalidone)” (lines 557-558) cut the ER bold-label text “bone-loss drugs:” and “blood-pressure drugs that reduce urinary calcium loss:”. The labels are no longer verbatim, and the terms are left unexplained.
- 7.2 — Supplement risks missing from summary: At-A-Glance (line 433) leaves out the Conclusion’s statement that the supplement’s risks mirror those of calcium supplements in general, so the only safety statement covers the toothpaste.
Fixes 26/09/2026 05:34
- 2.7 / 4.2 / 4.3 — Gate labels restored verbatim: Put back the ER glosses “high blood calcium” for hypercalcemia, “bone-loss drugs:” in the Bisphosphonates label, and “blood-pressure drugs that reduce urinary calcium loss:” in the Thiazide diuretics label.
- 7.2 — Supplement risks added to summary: Rewrote At-A-Glance to add “Its risks mirror those of calcium supplements.” It was tightened elsewhere to stay within 70 words.
Issues 26/09/2026 05:30
- 2.5 / 2.6 / 2.9 — Imperative instruction to reader: The Protocol cell [action_1_sub] (line 450) ends with “spit without rinsing”, an imperative that addresses the reader and gives guidance instead of presenting the ER statement that “trial protocols have users spit without rinsing” (ER line 341).
- 2.7 — Unexplained abbreviation “HAp”: The Protocol panel uses “HAp” in [action_1_value] and [action_1_sub] (lines 447 and 450) without spelling it out anywhere on the sheet, where the plain term “hydroxyapatite” would do.
Fixes 26/09/2026 05:30
- 2.5 / 2.6 / 2.9 — Imperative rinse instruction removed: In [action_1_sub], changed “spit without rinsing” to “no rinsing after spitting in trial protocols”, so it states the ER protocol and no longer gives the reader an instruction.
- 2.7 — “HAp” abbreviation replaced: In [action_1_value], changed “About 10% HAp toothpaste” to “About 10% hydroxyapatite toothpaste”. In [action_1_sub], changed “Micro- or nano-HAp” to “Micro- or nano-sized particles”.